SMAFIRA_Methods  

Documents (644) JSON TSV

source DB source ID text size updated at # proj. # Ann. updated_at
PubMed 21542674 Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hosp 2.79 KB 2019-12-06 8 0
-
PubMed 21711119 Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting. BACKGROUND: It is recommended that patients initiate triple ant 2.44 KB 2019-12-10 5 0
-
PubMed 21533811 Comparative clinical effectiveness of various 5-HT3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice. 2.09 KB 2019-12-10 5 0
-
PubMed 23814652 Palonosetron has superior prophylactic antiemetic efficacy compared with ondansetron or ramosetron in high-risk patients undergoing laparoscopic surgery: a prospective, randomized, double-blinded stud 1.95 KB 2019-12-10 6 0
-
PubMed 23170032 Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy. BACKGROUND: The second-generation serotoni 2 KB 2019-12-10 5 0
-
PubMed 23984894 Palonosetron for the prevention of chemotherapy-induced nausea and vomiting. Chemotherapy-induced nausea and vomiting (CINV) remains both a feared side effect of cancer treatment and a focus of many s 908 Bytes 2019-12-06 5 0
-
PubMed 23313773 Development of an enzyme-linked immunosorbent assay for detection of cellular and in vivo LRRK2 S935 phosphorylation. After the discovery of kinase activating mutations in leucine-rich repeat kinase 2 1.79 KB 2016-01-12 7 0
-
PubMed 24790242 An evaluation of potential signals for ventricular arrhythmia and cardiac arrest with dolasetron, ondansetron, and granisetron in the fda combined spontaneous reporting system/adverse event reporting 3.44 KB 2019-12-10 5 0
-
PubMed 24991400 The Impact of 5-HT3RA Use on Cost and Utilization in Patients with Chemotherapy-Induced Nausea and Vomiting: Systematic Review of the Literature. BACKGROUND: Individual studies have assessed the impac 2.71 KB 2019-12-06 8 0
-
PubMed 24991390 Outcomes Associated with 5-HT3-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis. BACKGROUND: Chemotherapy-induced nausea and vomiting (CI 3.01 KB 2019-12-06 6 0
-